Caption Management’s Quince Therapeutics QNCX Stock Holding History

Caption Management’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-349	Closed	-$2.13M	–	1872
2021 Q3	$6.4M	Buy	+349	New	+$5.55M	0.07%	360

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caption Management's QNCX Position: Q4 2021 in Review

Caption Management sold out of Quince Therapeutics (QNCX) in Q4 2021, closing a stake of 349 shares — an estimated $2.13M sold.

Caption Management first reported a position in QNCX in Q3 2021 and held it in 1 quarter. The position peaked at $6.4M in Q3 2021. 97 funds tracked by Wall St. Rank hold QNCX as of Q4 2021.

Caption Management reported no remaining Quince Therapeutics position as of Q4 2021 after selling out during the quarter.
Caption Management sold 349 Quince Therapeutics shares in Q4 2021, an estimated $2.13M.
Caption Management first reported a position in Quince Therapeutics in Q3 2021 and held it in 1 quarter.
Caption Management's Quince Therapeutics position peaked at $6.4M in Q3 2021.
97 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2021.

Based on Caption Management's 13F filing for Q4 2021, filed 11 Feb 2022.